Daratumumab-mediated lysis of primary multiple myeloma cells is enhanced in combination with the human anti-KIR antibody IPH2102 and lenalidomide
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Despite recent treatment improvements, multiple myeloma remains an incurable disease. Since antibody-dependent cell-mediated cytotoxicity is an important effector mechanism of daratumumab, we explored the possibility of improving daratumumab-mediated cell-mediated cytotoxicity by blocking natural killer cell inhibitory receptors with the human monoclonal anti-KIR antibody IPH2102, next to activation of natural killer cells with the immune modulatory drug lenalidomide. In 4-hour antibody-dependent cell-mediated cytotoxicity assays, IPH2102 did not induce lysis of multiple myeloma cell lines, but it did significantly augment daratumumab-induced myeloma cell lysis. Also in an ex vivo setting, IPH2102 synergistically improved daratumumab-dependent lysis of primary myeloma cells in bone marrow mononuclear cells (n=21), especially in patients carrying the FcγRIIIa-158F allele or the FcγRIIa-131R allele, who bind IgG1 with lower affinity than patients carrying the FcγRIIIa-158V allele or the FcγRIIa-131H allele. Finally, a further synergistically improved myeloma cell lysis with the daratumumab-IPH2102 combination was observed by adding lenalidomide, which suggests that more effective treatment strategies can be designed for multiple myeloma by combining daratumumab with agents that independently modulate natural killer cell function.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Functions of natural killer cells
Vivier, E., Tomasello, E., Baratin, M., Walzer, T., & Ugolini, S. (2008) · Nature Immunology · doi:10.1038/ni1582 · Cited by 3,943
de Weers, M., Tai, Y.-T., van der Veer, M. S., Bakker, J. M., Vink, T., Jacobs, D. C. H., Oomen, L. A., Peipp, M., Valerius, T., Slootstra, J. W., et al. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1003032 · Cited by 1,037
Self-citationKumar, S. K., Lee, J. H., Lahuerta, J. J., Morgan, G., Richardson, P. G., Crowley, J., Haessler, J., Feather, J., Hoering, A., Moreau, P., et al. (2012) · Leukemia · doi:10.1038/leu.2011.196 · Cited by 721
Self-citation
Cited by
CD38 antibodies in multiple myeloma: back to the future
van de Donk, N. W. C. J., Richardson, P. G., & Malavasi, F. (2018) · Blood · doi:10.1182/blood-2017-06-740944 · Cited by 493
Self-citationNijhof, I. S., Casneuf, T., van Velzen, J., van Kessel, B., Axel, A. E., Syed, K., Groen, R. W. J., van Duin, M., Sonneveld, P., Minnema, M. C., et al. (2016) · Blood · doi:10.1182/blood-2016-03-703439 · Cited by 393
Self-citationMonoclonal antibodies targeting CD 38 in hematological malignancies and beyond
van de Donk, N. W. C. J., Janmaat, M. L., Mutis, T., Lammerts van Bueren, J. J., Ahmadi, T., Sasser, A. K., Lokhorst, H. M., & Parren, P. W. H. I. (2016) · Immunological Reviews · doi:10.1111/imr.12389 · Cited by 353
Self-citationCD38 Antibodies in Multiple Myeloma: Mechanisms of Action and Modes of Resistance
van de Donk, N. W. C. J., & Usmani, S. Z. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02134 · Cited by 354
Self-citationPreclinical efficacy of daratumumab in T-cell acute lymphoblastic leukemia
Bride, K. L., Vincent, T. L., Im, S.-Y., Aplenc, R., Barrett, D. M., Carroll, W. L., Carson, R., Dai, Y., Devidas, M., Dunsmore, K. P., et al. (2018) · Blood · doi:10.1182/blood-2017-07-794214 · Cited by 229
Metadata
- Authors
- Nijhof, I. S., van Bueren, J. J. L., van Kessel, B., Andre, P., Morel, Y., Lokhorst, H. M., van de Donk, N. W. C. J., Parren, P. W. H. I., & Mutis, T.
- Venue
- Haematologica
- Published
- 2014-12-15
- Volume
- 100
- Issue
- 2
- Pages
- 263-268
- ISSN
- 0390-6078 (ISSN-L)
- 1592-8721
- OpenAlex
- W2113261463
- Cited by
- 112
- References
- 3
- FWCI
- 7.55
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Daratumumab-mediated lysis of primary multiple myeloma cells is enhanced in combination with the human anti-KIR antibody IPH2102 and lenalidomide. https://app.cochat.ai/papers/10.3324/haematol.2014.117531
- The paper
- Nijhof, I. S., van Bueren, J. J. L., van Kessel, B., Andre, P., Morel, Y., Lokhorst, H. M., van de Donk, N. W. C. J., Parren, P. W. H. I., & Mutis, T. (2015). Daratumumab-mediated lysis of primary multiple myeloma cells is enhanced in combination with the human anti-KIR antibody IPH2102 and lenalidomide. Haematologica. https://doi.org/10.3324/haematol.2014.117531
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.